Welcome to our dedicated page for Meihua International Medical Technologies Co., Ltd. SEC filings (Ticker: MHUAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Meihua International Medical Technologies Co., Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Meihua International Medical Technologies Co., Ltd.'s regulatory disclosures and financial reporting.
Meihua International Medical Technologies Co., Ltd. filed an amended report to correct clerical errors in an earlier description of its October 2025 private placement. The company had agreed to sell 40,000,000 ordinary shares at a purchase price of $0.38 per share for gross proceeds of $15.2 million to several non-U.S. purchasers under Regulation S.
According to the updated disclosure, the company issued 24,000,000 ordinary shares to these purchasers on October 17, and on January 20, 2026 it issued the remaining 160,000 class A ordinary shares, par value $0.05 per share, after a 100:1 split and adoption of a dual-class structure, completing the October offering. The company reports 857,914 issued and outstanding class A ordinary shares as of January 20, 2026.